ClearColi as a platform for untagged pneumococcal surface protein a production: cultivation strategy, bioreactor culture, and purification

Translated title
ClearColi como plataforma para produção de proteína a de superfície pneumocócica não marcada: estratégia de cultivo, cultura em biorreator e purificação

Publication type
Article
Language
English
Access rights
Restricted access
Appears in Collections:
Metrics
Abstract
Several studies have searched for new antigens to produce pneumococcal vaccines that are more effective and could provide broader coverage, given the great number of serotypes causing pneumococcal diseases. One of the promising subunit vaccine candidates is untagged recombinant pneumococcal surface protein A (PspA4Pro), obtainable in high quantities using recombinant Escherichia coli as a microbial factory. However, lipopolysaccharides (LPS) present in E. coli cell extracts must be removed, in order to obtain the target protein at the required purity, which makes the downstream process more complex and expensive. Endotoxin-free E. coli strains, which synthesize a nontoxic mutant LPS, may offer a cost-effective alternative way to produce recombinant proteins for application as therapeutics. This paper presents an investigation of PspA4Pro production employing the endotoxin-free recombinant strain ClearColi® BL21(DE3) with different media (defined, auto-induction, and other complex media), temperatures (27, 32, and 37 °C), and inducers. In comparison to conventional E. coli cells in a defined medium, ClearColi presented similar PspA4Pro yields, with lower productivities. Complex medium formulations supplemented with salts favored PspA4Pro yields, titers, and ClearColi growth rates. Induction with isopropyl-β-D-thiogalactopyranoside (0.5 mM) and lactose (2.5 g/L) together in a defined medium at 32 °C, which appeared to be a promising cultivation strategy, was reproduced in 5 L bioreactor culture, leading to a yield of 146.0 mg PspA4Pro/g dry cell weight. After purification, the cell extract generated from ClearColi led to 98% purity PspA4Pro, which maintained secondary structure and biological function. ClearColi is a potential host for industrial recombinant protein production.
Reference
Cardoso VM., Paredes SA.H., Campani G, Gonçalves VM, Zangirolami TC.. ClearColi as a platform for untagged pneumococcal surface protein a production: cultivation strategy, bioreactor culture, and purification. Appl. Microbiol. Biotechnol.. 2022 Jan;106:1011–1029. doi:10.1007/s00253-022-11758-9.
Link to cite this reference
https://repositorio.butantan.gov.br/handle/butantan/4098
URL
https://doi.org/10.1007/s00253-022-11758-9
Issue Date
2022


Files in This Item:

Existing users please Login
s00253-022-11758-9.pdf
Description:
Size: 2 MB
Format: Adobe PDF
Embargoed until January 1, 2099    Request a copy
Show full item record

The access to the publications deposited in this repository respects the licenses from journals and publishers.